An Enzyme-Generated Fragment of Tau Measured in Serum Shows an Inverse Correlation to Cognitive Function

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Henriksen, Kim ^a   Wang, Yaguo ^b   Sørensen, Mette G ^a   Barascuk, Natasha ^a   Suhy, Joyce ^c   Pedersen, Jan T ^d   Duffin, Kevin L ^e   Dean, Robert A ^e   Pajak, Monika ^a   Christiansen, Claus ^a   Zheng, Qinlong ^b   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Nordic Bioscience Beijing   (China)

^c SYNARC INC   (United States)

^d H LUNDBECK A S   (Denmark)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; BIOLOGICAL MARKER; MUTANT PROTEIN; PEPTIDE FRAGMENT; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN LEVEL; BRAIN TISSUE; COGNITION; CONTROLLED STUDY; CROSS REACTION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUROLOGIC EXAMINATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; SCORING SYSTEM; TAUOPATHY; TRANSGENIC MOUSE;

ADAM PROTEINS; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; COGNITION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS;

EID: 84878078532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064990     Document Type: Article

References (20)

1. Corbett A, Smith J, Ballard C, (2012) New and emerging treatments for Alzheimer's disease. Expert Rev Neurother. 12: 535-543.
2. Hampel H, Lista S, Khachaturian ZS, (2012) Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8: 312-336.
3. Blennow K, (2010) Biomarkers in Alzheimer's disease drug development. Nat Med. 16: 1218-1222.
4. Cummings JL, (2011) Biomarkers in Alzheimer's disease drug development. Alzheimers Dement (7) (): e13-e44.
5. Wang Y, Sorensen MG, Zheng Q, et al. (2012) Will Post-translational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias? Int J Alz Disease 2012: 209409.
6. Reifert J, Hartung-Cranston D, Feinstein SC, (2011) Amyloid {beta}-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation. J Biol Chem. 286: 20797-20811.
7. Karsdal MA, Henriksen K, Leeming DJ, et al. (2010) Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin Biochem. 43: 793-804.
8. De SB, (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev. 90: 465-494.
9. Barascuk N, Veidal SS, Larsen L, et al. (2010) A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 43: 899-904.
10. Gefter ML, Margulies DH, Scharff MD, (1977) A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 3: 231-236.
11. Henriksen K, Gram J, Schaller S, et al. (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol. 164: 1537-1545.
12. Silverberg GD, Mayo M, Saul T, et al. (2008) Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology. 71: 202-209.
13. McKhann G, Drachman D, Folstein M, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34: 939-944.
14. Fama R, Sullivan EV, Shear PK, et al. (1997) Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer disease. Arch Neurol. 54: 719-728.
15. Smith GE, Ivnik RJ, Malec JF, et al. (1994) Psychometric Properties of the Mattis Dementia Rating Scale. Assessment. 1: 123-132.
16. Sahara N, DeTure M, Ren Y, et al. (2013) Characteristics of TBS-Extractable Hyperphosphorylated Tau Species: Aggregation Intermediates in rTg4510 Mouse Brain. J Alzheimers Dis. 33: 249-63.
17. Schmidt R, Freidl W, Fazekas F, et al. (1994) The Mattis Dementia Rating Scale: normative data from 1,001 healthy volunteers. Neurology. 44: 964-966.
18. Yaffe K, Weston A, Graff-Radford NR, et al. (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 305: 261-266.
19. Barten DM, Cadelina GW, Hoque N, et al. (2011) Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis. 24: 127-141.
20. Rascovsky K, Salmon DP, Hansen LA, Galasko D, (2008) Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. J Int Neuropsychol Soc. 14: 373-383.